Role of novel targeted therapies in the clinic

Por Herbst, R S
Publicado em 2005

Targeting key pathways in tumour growth and development

Por Herbst, R S
Publicado em 2005

Herellea corenal ulcer associated with the use of soft contact lenses.

Por Herbst, R W
Publicado em 1972

The juxtamembrane region of MuSK has a critical role in agrin-mediated signaling.

Por Herbst, R, Burden, S J
Publicado em 2000

Phosphatidylinositol 3'-kinase associates with p145c-kit as part of a cell type characteristic multimeric signalling complex.

Por Shearman, M S, Herbst, R, Schlessinger, J, Ullrich, A
Publicado em 1993

Recruitment of the protein tyrosine phosphatase CSW by DOS is an essential step during signaling by the sevenless receptor tyrosine kinase.

Por Herbst, R, Zhang, X, Qin, J, Simon, M A
Publicado em 1999

The state of cellular differentiation determines the activity of the adenovirus E1A enhancer element: evidence for negative regulation of enhancer function.

Por Herbst, R S, Pelletier, M, Boczko, E M, Babiss, L E
Publicado em 1990

Regulation of adenovirus and cellular gene expression and of cellular transformation by the E1B-encoded 175-amino-acid protein.

Por Herbst, R S, Hermo, H, Fisher, P B, Babiss, L E
Publicado em 1988

Positive and negative regulatory elements in the mouse albumin enhancer.

Por Herbst, R S, Friedman, N, Darnell, J E, Babiss, L E
Publicado em 1989

The mouse albumin enhancer contains a negative regulatory element that interacts with a novel DNA-binding protein.

Por Herbst, R S, Boczko, E M, Darnell, J E, Babiss, L E
Publicado em 1990

Surrogate markers in antiangiogenesis clinical trials

Por Davis, D W, McConkey, D J, Abbruzzese, J L, Herbst, R S
Publicado em 2003

THE CHANGING FACE OF PHASE I CANCER CLINICAL TRIALS: NEW CHALLENGES IN STUDY REQUIREMENTS

Por Craft, BS, Kurzrock, R, Lei, X, Herbst, R, Lippman, S, Fu, S, Karp, DD
Publicado em 2009

EGFR biomarkers predict benefit from vandetanib in combination with docetaxel in a randomized phase III study of second-line treatment of patients with advanced non-small cell lung...

Por Heymach, J. V., Lockwood, S. J., Herbst, R. S., Johnson, B. E., Ryan, A. J.
Publicado em 2014

Musk Kinase Activity is Modulated By A Serine Phosphorylation Site in The Kinase Loop

Por Camurdanoglu, B. Z., Hrovat, C., Dürnberger, G., Madalinski, M., Mechtler, K., Herbst, R.
Publicado no Sci Rep (2016)

Corrigendum: MuSK Kinase Activity is Modulated By A Serine Phosphorylation Site in The Kinase Loop

Por Camurdanoglu, B. Z., Hrovat, C., Dürnberger, G., Madalinski, M., Mechtler, K., Herbst, R.
Publicado no Sci Rep (2016)

HER2 drives Mucin-like 1 to control proliferation in breast cancer cells

Por Conley, S J, Bosco, E E, Tice, D A, Hollingsworth, R E, Herbst, R, Xiao, Z
Publicado no Oncogene (2016)

Evaluation of pharmacodynamic biomarkers in a Phase 1a trial of dulanermin (rhApo2L/TRAIL) in patients with advanced tumours

Por Pan, Y, Xu, R, Peach, M, Huang, C-P, Branstetter, D, Novotny, W, Herbst, R S, Eckhardt, S G, Holland, P M
Publicado em 2011

Phase I study of axitinib combined with paclitaxel, docetaxel or capecitabine in patients with advanced solid tumours

Por Martin, L P, Kozloff, M F, Herbst, R S, Samuel, T A, Kim, S, Rosbrook, B, Tortorici, M, Chen, Y, Tarazi, J, Olszanski, A J, Rado, T, Starr, A, Cohen, R B
Publicado em 2012

CD19-positive antibody-secreting cells provide immune memory

Por Groves, C. J., Carrell, J., Grady, R., Rajan, B., Morehouse, C. A., Halpin, R., Wang, J., Wu, J., Shrestha, Y., Rayanki, R., Kolbeck, R., Wang, Y., Herbst, R.
Publicado no Blood Adv (2018)

Phase I trial of axitinib combined with platinum doublets in patients with advanced non-small cell lung cancer and other solid tumours

Por Kozloff, M F, Martin, L P, Krzakowski, M, Samuel, T A, Rado, T A, Arriola, E, De Castro Carpeño, J, Herbst, R S, Tarazi, J, Kim, S, Rosbrook, B, Tortorici, M, Olszanski, A J, Cohen, R B
Publicado em 2012